KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Research & Development (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of Research & Development readings, the most recent being $50.1 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 34.37% to $50.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $243.8 million, a 42.51% decrease, with the full-year FY2025 number at $243.8 million, down 42.51% from a year prior.
  • Research & Development hit $50.1 million in Q4 2025 for Ginkgo Bioworks Holdings, down from $69.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $985.0 million in Q4 2021 to a low of $50.1 million in Q4 2025.
  • Median Research & Development over the past 5 years was $125.6 million (2023), compared with a mean of $172.5 million.
  • Biggest five-year swings in Research & Development: surged 1509.75% in 2021 and later tumbled 81.98% in 2022.
  • Ginkgo Bioworks Holdings' Research & Development stood at $985.0 million in 2021, then tumbled by 81.98% to $177.5 million in 2022, then crashed by 34.08% to $117.0 million in 2023, then plummeted by 34.74% to $76.4 million in 2024, then tumbled by 34.37% to $50.1 million in 2025.
  • The last three reported values for Research & Development were $50.1 million (Q4 2025), $69.4 million (Q3 2025), and $53.4 million (Q2 2025) per Business Quant data.